Who Owns Aytu Bioscience


Aytu BioScience, Inc. The Company focuses on hypogonadism, prostate cancer, urinary tract infections and male infertility. 30, with a volume of 299,617 shares changing hands. The transaction was announced September 12, 2019 and is expected to close as early as December 2019, subject to customary closing conditions and regulatory approvals. 24%) and BlackRock Inc. The COVID-19 IgG/IgM is a rapid test intended for the presumptive qualitative detection of IgG/IgM antibodies from the 2019-nCoV in blood samples from individuals with signs and symptoms of infection who are suspected of Sars Cov-2. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced the signing of an exclusive distribution agreement for MiOXSYS® with GryNumber Health a leading specialty healthcare company serving the fertility market throughout Central and. Aytu BioScience is a commercial-stage specialty life sciences company focused on global commercialization of novel products in the field of urology, with a focus on products addressing vitality. acquired a new position in Aytu BioScience, Inc. ), a personal health and wellness company focused on women's sexual wellbeing and intimacy. A look at the shareholders of Aytu BioScience, Inc. 6 million worth of NATESTO® purchase orders from its U. Next >> You. Aytu also now owns wholly-owned subsidiary Aytu Women's Health (formerly Nuelle, Inc. decreased its Aytu BioScience Inc. is a healthcare company which focused on commercialization of novel products in the field of urology. It also offers custom milling services out of its. shares by 0. Aytu also now wholly-owns its subsidiary Aytu Women's Health (formerly Nuelle, Inc. Ampio CEO Michael Macaluso explained, "Ampio owns 81. This is a no-brainer for any cannabis producing company, as it essentially retained the money it spent for the equipment, which is now in full operation. 80%, hinting the company’s progress in the upcoming progress. Regoxidine® is indicated for hair treatment and regrowth and. The Turkish chef owns Nusr-Et, a chain of steakhouses in Turkey, Abu Dhabi and Dubai. Green is a highly accomplished CFO, who brings an extensive array of financial, accounting, and operational. 6 million worth of NATESTO® purchase orders from its U. , Delaware corporation, having offices at 373. Based on an average trading volume of 966,600 shares, the days-to-cover ratio is […]. AYTU has been the topic of several research analyst reports. is a healthcare company which focused on commercialization of novel products in the field of urology. LEAKED: Video PROVES Russian President Vladimir Putin Owns Bitcoin [Probably] + Jack Talks Bitcoin 👍. that a Party owns or has a license to such item or right and has the ability to grant to the other Party a license or sublicense under such item or right as provided for in this Agreement without violating the terms of any agreement or other arrangement with any Third Party in existence,. In an interview with NBC News , he explained the special connection he has with his meals. The Company focuses on hypogonadism, prostate cancer, urinary tract infections and male infertility. 56, but opened at $1. Sorrento Therapeutics Inc (NASDAQ:SRNE) was up 12. The video segments and articles note: Aytu BioScience has partnered with a Hong Kong company to distribute test kits that can provide results in 2-10 minutes and Aytu BioScience has already ordered 100,000 kits for distribution. 32) earnings per share for the quarter, missing the Zacks consensus estimate of ($0. After selling 95,269 shares in the last quarter, the firm now controls 0 shares of Aytu BioScience Inc. raised its holdings in Aytu Bioscience by 24. , a specialty pharmaceutical company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), cough and upper respiratory symptoms, insomnia, and male infertility in the United States and internationally. The firm owned 9,300 shares of the closed-end fund’s stock after selling 1,425 shares during the period. Aytu BioScience, Inc. (NASDAQ:AYTU) have power over the company. (DHT): This company that owns and operates crude oil tankers has a Zacks Rank #2 and. Positive Press Coverage Likely to Impact Aytu Bioscience (NASDAQ:AYTU) Share Price $153. The stock was sold at an average price of $11. The address of the Issuer's principal executive offices is 373 Inverness Parkway, Suite 206, Englewood, Colorado 80112. , a personal health and wellness company focused on women's sexual wellbeing and intimacy that markets Fiera, a personal care device for women that is scientifically proven to enhance physical arousal and sexual desire. The COVID-19 IgG/IgM is a rapid test intended for the presumptive qualitative detection of IgG/IgM antibodies from the 2019-nCoV in blood samples from individuals with signs and symptoms of infection who are suspected of Sars Cov-2. Aytu BioScience is a commercial-stage specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, with a focus on products addressing vitality, sexual wellness, and reproductive health. is a commercial-stage healthcare company focused on acquiring, developing and commercializing products in the field of urology. 6 to Schedule 13D relates to the Issuer's Common Stock, par value $. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. Aytu Bioscience's stock is owned by many different of institutional and retail investors. (NASDAQ: AYTU) announced this month the establishment of a COVID-19 inquiry procedure to ensure the company adequately responds to inbound inquires from professionals and the. 5% in the fourth quarter. 5 million of equity units. In order to streamline and effectively capture the significant number of inbound inquiries related to the COVID-19 IgG/IgM Rapid Test. Aytu BioScience (NASDAQ: AYTU) is a specialty pharmaceutical company focused on commercializing novel products in large therapeutic areas. Aytu BioScience is a commercial-stage specialty pharmaceutical company focused on commercializing novel products that address significant patient needs. Several analysts have […]. Aytu BioScience is a commercial-stage specialty life sciences company focused on global commercialization of novel products in the field of urology, with a focus on products addressing vitality. This LICENSE AND SUPPLY AGREEMENT (this “ Agreement ”) is made and effective as of April 22, 2016 (the “ Effective Date ”) by and among Acerus Pharmaceuticals SRL, a society with restricted liability, having its principal office at Suite B, Durants Business Center, Durants, Christ Church, Barbados (“ Acerus ”) and Aytu Bioscience, Inc. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. , a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs announced. ENGLEWOOD, Colo. Prior to joining Ampio Pharmaceuticals in June 2014, he provided financial and operational. Disbrow serves as the Chairman and Chief Executive Officer of Aytu BioScience, Inc. Distributed by Public, unedited and unaltered, on 31 January 2020 00:14:04 UTC. 37 million dollars. Aytu Bioscience Inc (NASDAQ:AYTU) CEO Joshua R. Our mission is to create breakthrough technologies to drug previously challenging targets (GPCRs, ion channels, pMHC complexes, condition-specific binders, anti-idiotypes, and broadly neutralizing viral epitopes). ENGLEWOOD, CO / ACCESSWIRE / April 13, 2020 / Aytu BioScience, Inc. About Aytu BioScience, Inc. BlackRock Inc. For added context, Aytu BioScience is a bio-tech/pharmaceutical company with a stock market presence, that has recently signed "a definitive agreement (the "Agreement") with Singapore-based Biolidics, Limited (SGX: 8YY; "Biolidics") to exclusively distribute Biolidics' COVID-19 IgG/IgM Rapid Test in the United States. (NASDAQ:AKRX)’s share price gapped up before the market opened on Monday. On Aytu BioScience's (AYTU) upcoming earnings call, investor focus will be on its diversified portfolio of medicines approved to treat ailments like low testosterone, insomnia and male infertility. Searle & CO. Based on an average trading volume of 966,600 shares, the days-to-cover ratio is […]. Aytu Women's Health markets Fiera, a personal care product for women that is scientifically proven to enhance physical arousal and sexual desire. (FNM), which owns and operates FinancialNewsMedia. Aytu BioScience is a commercial-stage specialty pharmaceutical company focused on commercializing novel products that address significant patient needs. com, is a third party publisher and news dissemination service provider, which. relating to its purchase agreement with Cerecor Inc. Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) was the recipient of a large drop in short interest in the month of March. Annual Aytu BioScience TTM sales up to December 2018 were $4. Ricky Lopez owns three "virtual restaurants" and one traditional eatery in San Francisco (Courtesy: Ricky Lopez) More Lopez, who owns three “virtual restaurants” in addition to one traditional eatery, is able to operate his virtual chains as extensions of his popular brick and mortar location. About Aytu BioScience, Inc. I have some SEO tests on my channel. Largest shareholders include. Aytu Bioscience (NASDAQ:AYTU)'s stock had its "buy" rating restated by equities researchers at Northland Securities in a note issued to investors on Tuesday, AnalystRatings. The Turkish chef owns Nusr-Et, a chain of steakhouses in Turkey, Abu Dhabi and Dubai. Its products include Natesto, Tuzistram, ZolpiMist and. ENGLEWOOD, Colo. (NASDAQ:FATE) stock increased by 21. YouTube takes down biotech company’s video describing their novel UV light treatment for COVID-19 patients. Consumers Who Purchased. Aytu BioScience, Inc. Aytu BioScience is a commercial-stage specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, with a foc us on products addressing vitality, sexual wellness, and reproductive health. For more information visit aytubio. 59M shares, which means that the short-interest ratio is just 0. Food and Drug Association (FDA) for its COVID-19 rapid test. ENGLEWOOD, Colo. Basic Fit owns and operates fitness chains in the Netherlands and Belgium. Based on an average daily trading volume, of 6,610,000 shares, the short-interest ratio is […]. Large shareholders that own 10% or more of a company’s shares are required […]. Aytu BioScience, Inc. ENGLEWOOD, CO. This is a no-brainer for any cannabis producing company, as it essentially retained the money it spent for the equipment, which is now in full operation. Greg has worked with Aytu BioScience's management team since the company's inception in April 2015. About Aytu BioScience, Inc. com, is a third party publisher and news dissemination service provider, which disseminates. 0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The president subsequently claimed on Friday that he was being "sacrastic. Interactive chart of Biogen (BIIB) annual worldwide employee count from 2006 to 2020. (NASDAQ:ECOR) shares rose 108. Aytu BioScience is a commercial-stage specialty life sciences company focused on global commercialization of novel products in the field of urology, with a focus on products addressing vitality. (AYTU) May. Food and Drug Association (FDA) for its COVID-19 rapid test. acquired a new position in Aytu BioScience, Inc. 56, but opened at $1. , November 17, 2015 /PRNewswire/ — Ampio Pharmaceuticals, Inc. 86 and its 200-day moving average is $1. (NASDAQ:DHIL) Director James F. Aytu also now owns wholly-owned subsidiary Nuelle, Inc. Find out the total of insider shares held, purchased and sold. The transaction was announced September 12, 2019 and is expected to close as early as December 2019, subject to customary closing conditions and regulatory approvals. Following the transaction, the insider now directly owns 26,616 shares in the company, valued at approximately $297,300. (NASDAQ:AYTU) About Us. SEC filings show that Heyden Olaf Robert bought 20,000 shares of the company's common stock on Mar 13 at a price of $5. These purchase orders. 90 per share, with a total value of $70,909. / Altium Capital Management Lp - ACQUISITION OF BENEFICIAL OWNERSHIP Passive Investment. Aytu BioScience, Inc. suggested on Thursday that injecting disinfectant or ultraviolet light into the body could be a way to kill the coronavirus, his comments were widely criticized as harmful. Gainers • electroCore, Inc. TPTX Stock Analysis Overview. AYTU BIOSCIENCE, INC. purchased a new position in Aytu Bioscience in the second quarter worth about $36,000. Even easier for some, many like to be delivered opportunity, so, here you go. For more information visit aytubio. Aytu BioScience (AYTU) has 1 split in our AYTU split history database. Entergy owns and operates power plants with approximately 30,000 megawatts of electric generating capacity, including nearly 9,000 megawatts. 2019-10-21 sec. Which institutional investors are buying and selling shares of Aytu Bioscience (NASDAQ:AYTU) stock? View the most recent institutional ownership activity and 13F transactions for AYTU stock at MarketBeat. The stocks 50 day moving average is $0. President Trump has now put Mr. The stock had previously closed at $1. 41 per share for a total of $108203. v) Announces 2. The present dividend yield for AYTU owners is set at 0, marking the return investors will get regardless of the company's performance in the upcoming period. A number of analysts have recently issued reports on AYTU shares. 18, 2017 /PRNewswire/ -- Aytu BioScience, Inc. Zacks Investment Research cut shares of Aytu Bioscience (NASDAQ:AYTU) from a hold rating to a sell rating in a research note released on Tuesday, Zacks. Approve, in accordance with Nasdaq Marketplace Rule 5635(d), the convertibility of the Company's Series F convertible preferred stock, par value $0. 56 during Friday’s pre-market session. Green as Chief Financial Officer. 9M Share Purchase by CEO, Mr. is a commercial-stage healthcare company focused on acquiring, developing and commercializing products in the field of urology. What this means: Turning Point Therapeutics Inc (TPTX) gets an Overall Rank of 60, which is an above average rank under InvestorsObserver's stock ranking system. Shares of Aytu Bioscience Inc (NASDAQ:AYTU) gapped down before the market opened on Thursday. 45, but opened at $1. The COVID-19 IgG/IgM is a rapid test intended for the presumptive qualitative detection of IgG/IgM antibodies from the 2019-nCoV in blood samples from individuals with signs and symptoms of infection who are suspected of Sars Cov-2. Find the latest Aytu BioScience, Inc. (FNM), which owns and operates FinancialNewsMedia. Breaking News Archive. 4% during trading on Friday. Pure Cycle owns land and water assets in the Denver, Colorado metropolitan area. YouTube takes down biotech company’s video describing their novel UV light treatment for COVID-19 patients. Aytu BioScience Inc. On Aytu BioScience's (AYTU) upcoming earnings call, investor focus will be on its diversified portfolio of medicines approved to treat ailments like low testosterone, insomnia and male infertility. Insider Trading - AYTU BIOSCIENCE INC Select Time period: 1 Month 2 Months 3 Months 6 Months 1 Year 2 Years 3 Years 4 Years 5 Years 6 Years 7 Years 8 Years 9 Years 10 Years 11 Years 12 Years 13 Years 14 Years 15 Years 16 Years 17 Years 18 Years 19 Years All Data. which are valued at $50,493. that a Party owns or has a license to such item or right and has the ability to grant to the other Party a license or sublicense under such item or right as provided for in this Agreement without violating the terms of any agreement or other arrangement with any Third Party in existence,. CorEnergy Infrastructure Trust, Inc. , valued at $4,763 with the latest closing price. DISCLAIMER: FN Media Group LLC (FNM), which owns and operates FinancialNewsMedia. 21%), Bank of New York Mellon Corp (0. ENGLEWOOD, CO, May 14, 2018 /ACCESSWIRE/ -- Aytu BioScience, Inc. now owns 249,848 shares of the company’s stock worth $302,000 after buying an additional 48,601 shares during the last quarter. The stock had previously closed at $1. Aytu BioScience, Inc. Our mission is to create breakthrough technologies to drug previously challenging targets (GPCRs, ion channels, pMHC complexes, condition-specific binders, anti-idiotypes, and broadly neutralizing viral epitopes). Aytu BioScience is a commercial-stage specialty pharmaceutical company focused on commercializing novel products that address significant patient needs. 37 million dollars. Aytu BioScience is a commercial-stage specialty life sciences company focused on global commercialization of novel products in the field of urology, with a focus on products addressing vitality. Aytu BioScience is a commercial-stage specialty pharmaceutical company focused on commercializing novel products that address significant patient needs. Aytu Bioscience Inc Com Par % of Funds with AYTU in top 20 holdings: 0. With the huge momentum gained on March 31st, it would be great to start April with just as big of a bang and list of penny stocks to watch including Aytu BioScience, Inc. Aytu BioScience, Inc. Potomac Law ("PLG") is serving as special M&A counsel to Innovus Pharmaceuticals, Inc. On November 2,. Aytu BioScience is a commercial-stage specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, with a foc us on products addressing vitality, sexual wellness, and reproductive health. , a specialty healthcare company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), insomnia, and male infertility in the United States and internationally. raised its holdings in Aytu Bioscience by 24. Aytu BioScience is pursuing an emergency use authorization with the FDA for the COVID-19 IgG/IgM test. “The shape of the meat and the taste of it starting from the top down is a part of me,”Gökçe explained. 01 Entry into a Material Definitive Agreement On November 29, 2018, Aytu BioScience, Inc. I am not native English speaker that's why I have accent. A look at the shareholders of Aytu BioScience, Inc. Aytu BioScience, Inc. Joined Oct 4, 2005 Messages 4,785 Location On the road. To find book value, add up everything the company owns in terms of assets, then subtract everything the company owes, such as debts and other liabilities. About Aytu BioScience, Inc. is a commercial-stage healthcare company focused on acquiring, developing and commercializing products in the field of urology. (), a specialty life sciences company focused on global commercialization of novel products in the field of urology, has highlighted its progress of the company's commercial strategy in the below letter to shareholders. Its products include Natesto, Tuzistram, ZolpiMist and. Announces Investigation of Aytu BioScience, Inc. 86% over the past 90 days. Address of issuer s principal executive offices 373 Inverness Parkway, Suite 206 Englewood, Colorado 80112 Item 2. boosted its holdings in Opiant Pharmaceuticals by 43. Aytu BioScience is a commercial-stage specialty life sciences company focused on global commercialization of novel products in the field of urology, with a focus on products addressing vitality. We are computational immuno-engineers. 59, with a volume of 9,679,057 shares traded. Even easier for some, many like to be delivered opportunity, so, here you go. Aytu BioScience expects to partner the product outside the U. Prior to joining Ampio Pharmaceuticals in June 2014, he provided financial and operational. , a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs announced. I am not native English speaker that's why I have accent. 1 million compared to $10. (NASDAQ: AYTU). About Aytu BioScience: Aytu Bioscience is a pharmaceutical company focused on identifying, acquiring, and commercializing products. Food and Drug Association (FDA) for its COVID-19 rapid test. You can write me in Instagram @stelmakdv. 5 million of equity units. The company markets a portfolio of prescription products addressing large therapeutic markets. ENGLEWOOD, Colo. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced seven presentations at the European Society of Human Reproduction and Embryology (ESHRE) meeting in Geneva, Switzerland. 5 million for. The Company also owns 75% of Production Resources Inc. (NYSE:BEN) by 13. About Aytu BioScience, Inc. One of those ways came through our newly formed relationship with a prominent Los Angeles hospital. Alpha Venture Capital Partners owns 16. ValuEngine upgraded Akorn from a “hold” […]. ("Aytu") vote on proposalsfour (collectively, the "Proposals") to: 1. , a Nevada corporation (the "Target"), Aytu Bioscience Inc. After this action, Rushing now owns 46,294 shares of T2 Biosystems, Inc. is a specialty pharmaceutical company, which focuses on identifying, acquiring, and commercializing novel products. (NASDAQ: AYTU) announced earlier this month the establishment of a COVID-19 inquiry procedure to ensure the company adequately responds to inbound inquires from professionals and the public. On November 2,. The Company has been in discussions with healthcare distributors, healthcare institutions, medical practices, and government agencies and is working quickly to begin distribution into the U. The most recent transaction is an insider purchase by STEIN KEVIN, the company's Director. 30, with a volume of 299,617 shares changing hands. Date/Time Headline; May 5, 2020: 5:07 PM EDT : Gatekeeper (GSI. Following the purchase, the insider now owns 232487. 48 million, a PE ratio of -0. Aytu BioScience, Inc. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. Food and Drug Association (FDA) for its COVID-19 rapid test. , valued at $4,763 with the latest closing price. 52, with a volume of 14,191,778 shares trading hands. , November 17, 2015 /PRNewswire/ — Ampio Pharmaceuticals, Inc. Following these latest developments, around 1. Find out the total of insider shares held, purchased and sold. Apply instantly. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs announced today the launch of Regoxidine®, an over-the-counter foam formulation of minoxidil available for use by both men and women. Interactive chart of Biogen (BIIB) annual worldwide employee count from 2006 to 2020. If you want to know who really controls Nabors Industries Ltd. Oil Companies That You Need To Check Out. Sabby Management, LLC discloses 9. The stock was sold at an average price of $11. 0001 per share (Title of Class of Securities. Webull Financial LLC is a member of Securities Investor Protection Corporation (SIPC), which protects securities customers of its members up to $500,000 (including $250,000 for claims for cash). raised its holdings in Aytu Bioscience by 24. 23 and a beta of 4. The suspension of Aytu BioScience’s account comes shortly after YouTube removed a video demonstrating the technology (which can be seen below on Vimeo). 0001 per share (the "Shares"). Aytu Bioscience, Inc. The company's fuel technology enables use of hydrocarbon based waste streams to be converted to fossil fuel substitutes. (NASDAQ: AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today announced the appointment of David A. (OTCQX: AYTU) a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced that it has received subscriptions for a private placement in the amount of approximately $11. 8 million in 2018. 30, with a volume of 299,617 shares changing hands. About Aytu BioScience, Inc. 7% during mid-day trading on Friday. 6 million ounces of gold), the Beaufor, Croinor Gold (see video), Fayolle, McKenzie Break and Swanson advanced projects, and the Camflo and Beacon mills. (Exact Name of Registrant as Specified in Charter) Delaware 001-38247 47-0883144 (State or Other Jurisdiction. , sold 5,808 shares at the value of $0. published this content on 23 December 2019 and is solely responsible for the information contained therein. Following the completion of the acquisition, the director now directly owns 32,000 shares […]. (often referred to as “Orient Gene”) recently acquired 100% interest and is the sole owner of Healgen Scientific. Aytu BioScience, Inc. (NYSE: CORR, CORRPrA), is a real estate investment trust (REIT) that owns critical energy assets, such as pipelines, storage terminals, and transmission and distribution assets. Several research firms […]. 's products include: Natesto® (testosterone) nasal gel, which is a testosterone replacement therapy for hypogonadism (low testosterone) in men; Tuzistra® XR, which is a codeine-based antitussive; ZolpiMist™, which is indicated for the short-term treatment. , a Delaware corporation and a wholly-owned Subsidiary of Aytu ("Merger Sub"). The company's earnings record has been dismal so far, having witnessed a negative surprise in two of the last three quarters while surpassing expectations in one. America's generally pro-Trump media site Fox News felt compelled to report today that "Some poison control centers reported a spike in calls following President Trump's suggestion that injecting disinfectant might help people infected with coronavirus. 19, 2017 /PRNewswire/ -- Aytu BioScience, Inc. Aytu BioScience, Inc, a specialty healthcare company, focuses on developing and commercializing novel products in the. is a commercial-stage healthcare company focused on acquiring, developing and commercializing products in the field of urology. Diamond Hill Investment Group, Inc. is a specialty healthcare company, which focuses on developing and commercializing novel products in the field of hypogonadism, insomnia and male infertility in the United States and internationally. Hoth Therapeutics Inc is a development-stage biopharmaceutical company. (AYTU) Analysis. Aytu BioScience is a commercial-stage specialty pharmaceutical company focused on commercializing novel products that address significant patient needs. published this content on 23 March 2020 and is solely responsible for the information contained therein. 42% and a negative net margin of 390. 1% in the third quarter. (NYSE:BEN) by 13. An increase of 30% from the average session volume of 78,756 shares. Disbrow acquired 55,000 shares of the firm's stock in a transaction on Thursday, December 19th. The Company focuses on hypogonadism, prostate cancer, urinary tract infecti ons and male infertility. 19, 2017 /PRNewswire/ -- Aytu BioScience, Inc. Searle & Co. (FNM), which owns and operates FinancialNewsMedia. during the first quarter, with the value of $142904, and Geode Capital Management LLC increased their stake in the company's shares by 0. The Company also owns 75% of Production Resources Inc. 9M Share Purchase by CEO, Mr. The primary care portfolio includes (i) Natesto®, the only FDA-approved. 17, for a total value of $324,488. is a commercial-stage healthcare company focused on acquiring, developing and commercializing products in the field of urology. Jonova inc Jonova inc. On March 10, 2020, Aytu BioScience (AYTU. (NASDAQ:AYTU) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. (NASDAQ: AYTU). 6% Stake In The Company Growth investors will appreciate the company because its revenue is growing at a high pace and its gross profit margins are also increasing. America's generally pro-Trump media site Fox News felt compelled to report today that "Some poison control centers reported a spike in calls following President Trump's suggestion that injecting disinfectant might help people infected with coronavirus. Ampio CEO Michael Macaluso explained, "Ampio owns 81. The company currently markets Natesto®, the only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or "Low T"). ValuEngine upgraded Akorn from a “hold” […]. 13% decline from 2018. The split for AYTU took place on August 13, 2018.   Aytu also now owns wholly-owned subsidiary Aytu Women's Health (formerly Nuelle, Inc. Aytu BioScience, Inc. Currently, most Americans are tested for COVID-19 using a nasal swab that produces results in 24 to 48 hours. Our commitment to improving peoples' health is unwavering. Following the transaction, the insider now directly owns 26,616 shares in the company, valued at approximately $297,300. Pharmaceutical Companies. G&A expenses for 2019 were $10. Aytu Bioscience Inc (NASDAQ:AYTU) major shareholder Armistice Capital Master Fund acquired 78,788 shares of Aytu Bioscience stock in a transaction dated Friday, December 20th. (NASDAQ: AYTU) announced earlier this month the establishment of a COVID-19 inquiry procedure to ensure the company adequately responds to inbound inquires from professionals and the public. The company currently markets a portfolio of prescription products addressing large primary care and pediatric markets. The present dividend yield for AYTU owners is set at 0, marking the return investors will get regardless of the company's performance in the upcoming period. Additionally, Aytu BioScience's Mioxsys is a novel, rapid semen analysis system, which has the potential to become a standard of care for treating male infertility caused by oxidative stress. 6 to Schedule 13D relates to the Issuer's Common Stock, par value $. 26, 2017 /PRNewswire/ -- Aytu BioScience, a specialty life sciences company focused on global commercialization of novel products in the field of urology, today provided an update on the ongoing launch of Natesto in the U. Here is the most factual reporting that I could find of what trump said. More… ~~~~~ We cannot buy masks for protection. 6% Stake In The Company. Aytu BioScience, Inc. com, is a third party publisher and news dissemination service provider, which. , a South Texas oil company. Aytu BioScience is a commercial-stage specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, with a focus on products addressing vitality, sexual wellness, and reproductive health. Aytu BioScience Consumer Health Subsidiary Launches Regoxidine(R), an FDA Approved Hair Regrowth Treatment Foam that Contains 5% Minoxidil and Targets Over 11 Million U. 83 per share, for a total transaction of $45,650. We are monitoring the COVID-19 situation and have taken steps to ensure that access and assistance for patients remain consistent. Top News Archive. Aytu Bioscience, Inc. Aytu BioScience promotes ultraviolet technology to kill Covid. 86 and its 200-day moving average is $1. 76% of the companys stock. Aytu was founded on therapeutic and diagnostic assets previously owned by Ampio Pharmaceuticals. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones. This was a 1 for 20 reverse split, meaning for each 20 shares of AYTU owned pre-split, the shareholder now owned 1 share. Aytu Bioscience shares last traded at $1. Hoth Therapeutics Inc is a development-stage biopharmaceutical company. 00/sh s (payable in cash and/or NantCell common stock at the election of each Altor BioScience stockholder) upon achievement of a regulatory milestone and a sales milestone. The Company currently markets a portfolio of prescription products addressing large primary care and pediatric markets. (AYTU) Analysis The present dividend yield for AYTU owners is set at 0, marking the return investors will get regardless of the company’s performance in the upcoming period. 80%, hinting the company’s progress in the upcoming progress. Aytu BioScience, Inc. licensee Aytu BioScience (NASDAQ: AYTU). 80%, hinting the company's progress in the upcoming progress. Insider Trading - AYTU BIOSCIENCE INC Select Time period: 1 Month 2 Months 3 Months 6 Months 1 Year 2 Years 3 Years 4 Years 5 Years 6 Years 7 Years 8 Years 9 Years 10 Years 11 Years 12 Years 13 Years 14 Years 15 Years 16 Years 17 Years 18 Years 19 Years All Data. Aytu was founded on therapeutic and diagnostic assets previously owned by Ampio Pharmaceuticals. The most recent rating by Citigroup, on Mar 4, is at …. The firm has a market capitalization of $16. The shares were bought at an average price of $95. ENGLEWOOD, Colo. is a commercial-stage healthcare company focused on acquiring, developing and commercializing products in the field of urology. AYTU / Aytu BioScience, Inc. Find out the total of insider shares held, purchased and sold. The stock had previously closed at $1. A new paradigm in antibody engineering and broad-spectrum vaccine design. 45, but opened at $1. SEC filings show that Heyden Olaf Robert bought 20,000 shares of the company's common stock on Mar 13 at a price of $5. For all upcoming news releases, articles, comments and questions, to stay updated and speak with management about Emerald Bay Energy. 6 million worth of NATESTO® purchase orders from its U. purchased a new position in Aytu Bioscience in the second quarter worth about $36,000. now owns 249,848 shares of the companys stock worth $302,000 after purchasing an additional 48,601 shares during the period. For more information visit aytubio. 2019-11-15 seekingalpha. 18, 2017 /PRNewswire/ -- Aytu BioScience, a specialty life sciences company focused on global commercialization of novel products in the field of urology, today announced that its shares of common stock were approved for listing on The NASDAQ Capital Market. The president subsequently claimed on Friday that he was being "sacrastic. Aytu products are as unique as our mission. raised its holdings in Aytu Bioscience by 24. purchased a new position in Aytu Bioscience in the second quarter worth about $36,000. Based on an average daily trading volume, of 6,610,000 shares, the short-interest ratio is […]. 25, 102,424 shares were traded during trading. Early in the Covid-19 pandemic, Aytu BioScience made a commitment to find ways to help. (AYTU): This specialty pharmaceutical company that focuses on developing and commercializing novel products has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus. Aytu BioScience is pursuing an emergency use authorization with the FDA for the COVID-19 IgG/IgM test. Currently, most Americans are tested for COVID-19 using a nasal swab that produces results in 24 to 48 hours. com, for 90 days. In the chart below below, we can see that institutions don’t own many shares in the company. The Company focuses on hypogonadism, prostate cancer, urinary tract infections and male infertility. Cruz Announces Investigation on Behalf of Aytu BioScience Inc. is a commercial-stage specialty healthcare company focused on urological and related conditions. This was a 1 for 20 reverse split, meaning for each 20 shares of AYTU owned pre-split, the shareholder now owned 1 share. 31, but opened at $0. The Company currently markets a portfolio of prescription products addressing large primary care and pediatric markets. North Carolina State is providing faulty Chinese KN95 masks to county level health workers. Find out the total of insider shares held, purchased and sold. com, is a third party publisher and news dissemination service provider, which. R&D expenses in 2019 were $11. The stock was sold at an average price of $11. The Company focuses on hypogonadism, prostate cancer, urinary tract infections and male infertility. published this content on 23 March 2020 and is solely responsible for the information contained therein. (NASDAQ:AYTU) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Get the latest updated list of insiders for Aytu BioScience, Inc. Ampio CEO Michael Macaluso explained, “Ampio owns 81. Several analysts have […]. 6 million ounces of gold), the Beaufor, Croinor Gold (see video), Fayolle, McKenzie Break and Swanson advanced projects, and the Camflo and Beacon mills. Aytu BioScience is a commercial-stage specialty pharmaceutical company focused on commercializing novel products that address significant patient needs. Largest shareholders include. Aytu BioScience, Inc. Webull Financial LLC is registered with and regulated by the Securities and Exchange Commission (SEC) and the Financial Industry Regulatory Authority (FINRA). Greg has worked with Aytu BioScience's management team since the company's inception in April 2015. , a Nevada corporation (the "Target"), Aytu Bioscience Inc. Aytu BioScience, Inc. Shares of Aytu Bioscience Inc (NASDAQ:AYTU) gapped down before the market opened on Thursday. during the first quarter, with the value of $142904, and Geode Capital Management LLC increased their stake in the company’s shares by 0. Aytu BioScience is a commercial-stage specialty life sciences company focused on global commercialization of novel products in the field of urology, with a focus on products addressing vitality. Aytu BioScience, Inc. A replay of the call will be available for fourteen days. (Exact Name of Registrant as Specified in Charter) Delaware 001-38247 47-0883144 (State or Other Jurisdiction. Webull Financial LLC is a member of Securities Investor Protection Corporation (SIPC), which protects securities customers of its members up to $500,000 (including $250,000 for claims for cash). On Aytu BioScience's (AYTU) upcoming earnings call, investor focus will be on its diversified portfolio of medicines approved to treat ailments like low testosterone, insomnia and male infertility. The company currently markets a portfolio of prescription products addressing large primary care and pediatric markets. (AYTU) stock quote, history, news and other vital information to help you with your stock trading and investing. Interactive chart of Biogen (BIIB) annual worldwide employee count from 2006 to 2020. (“Aytu”) to. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs announced today the launch of Regoxidine®, an over-the-counter foam formulation of minoxidil available for use by both men and women. Following the purchase, the insider now owns 232487. , Delaware corporation, having offices at 373. (“APBI”) (incorporated in Barbados), and Acerus Laboratories Inc. 80%, hinting the company’s progress in the upcoming progress. The suspension of Aytu BioScience’s account comes shortly after YouTube removed a video demonstrating the technology (which can be seen below on Vimeo). purchased a new position in Aytu Bioscience in the second quarter worth about $36,000. com and MarketNewsUpdates. The company currently markets eight prescription products. DISCLAIMER: FN Media Group LLC (FNM), which owns and operates FinancialNewsMedia. , a personal health and wellness company focused on women's sexual wellbeing and intimacy that markets Fiera, a personal care device for women that is scientifically proven to enhance physical arousal and sexual desire. Large shareholders that own 10% or more of a company's shares are required […]. About Aytu BioScience, Inc. com, is a third party publisher and news dissemination service provider, which. Aytu BioScience, Inc. ENGLEWOOD, Colo. Aytu Bioscience has a twelve month low of $0. AYTU has been the topic of several research analyst reports. North Carolina State is providing faulty Chinese KN95 masks to county level health workers. Sorrento Therapeutics Inc (NASDAQ:SRNE) was up 12. Announces Investigation of Aytu BioScience, Inc. ('Nuelle"), a women's sexual health company. Large shareholders that own 10% or more of a company's shares are required […]. 00% of Aytu BioScience Inc. The stock had previously closed at $2. View all Ashfield Healthcare jobs in Orlando, FL - Orlando jobs. Innovus Pharma is a wholly owned subsidiary of Aytu BioScience, Inc. now owns 249,848 shares of the companys stock worth $302,000 after purchasing an additional 48,601 shares during the period. In addition, the growth of sales from quarter to quarter is recording 77. Aytu BioScience, Inc. Searle & Co. 6 to Schedule 13D relates to the Issuer's Common Stock, par value $. 00/sh s (payable in cash and/or NantCell common stock at the election of each Altor BioScience stockholder) upon achievement of a regulatory milestone and a sales milestone. (often referred to as “Orient Gene”) recently acquired 100% interest and is the sole owner of Healgen Scientific. Find out the total of insider shares held, purchased and sold. Aytu BioScience Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs announced today the launch of Regoxidine®, an over-the-counter foam formulation of minoxidil available for use by both men and women. The COVID-19 IgG/IgM is a rapid test intended for the presumptive qualitative detection of IgG/IgM antibodies from the 2019-nCoV in blood samples from individuals with signs and symptoms of infection who are suspected of Sars Cov-2. (NASDAQ:AYTU) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Protected: Beyond Meat IPO: Tyson Foods Owns 6. ENGLEWOOD, Colo. AltMed owns 75% of the CRTCE, a fully operational ketamine The test kits were delivered to Denver Chief of Police Paul Pazen and members of his leadership team at Aytu BioScience's corporate. Food and Drug Administration (FDA) that the company may begin distribution of its Coronavirus Disease 2019 ("COVID-2019") IgG/IgM Rapid Test throughout the United States. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 23, 2018 AYTU BIOSCIENCE, INC. About Aytu Bioscience Inc. Following the purchase, the insider now owns 232487. (OTCQX: AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today announced that its shares of common stock were approved for listing on The NASDAQ Capital Market. Aytu Bioscience, Inc. , a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced the accelerated launch of ZolpiMist™, an oral spray formulation of zolpidem tartrate (brand name Ambien®) and the only FDA-approved oral spray prescription sleep aid. (NASDAQ:PEP) was the target of a significant drop in short interest in the month of March. ), a personal health and wellness company focused on women's sexual wellbeing and intimacy. is a commercial-stage healthcare company focused on acquiring, developing and commercializing products in the field of urology. This Waiver and Amendment (this "Waiver") is made effective as of November 29, 2019, by and between Acerus Pharmaceuticals Corporation, a Canadian corporation, having offices at 2486 Dunwin Drive, Mississauga, ON L5L IJ9, Canada ("Acerus"), and Aytu Bioscience, Inc. Searle & CO. Aytu Bioscience, Inc - WAIVER AND AMENDMENT (December 2nd, 2019). Additionally, Aytu BioScience's Mioxsys is a novel, rapid semen analysis system, which has the potential to become a standard of care for treating male infertility caused by oxidative stress. The company markets a portfolio of prescription products addressing large therapeutic markets. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 23, 2018 AYTU BIOSCIENCE, INC. 32) EPS for the quarter, missing the consensus estimate of ($0. (often referred to as “Orient Gene”) recently acquired 100% interest and is the sole owner of Healgen Scientific. The present dividend yield for AYTU owners is set at 0, marking the return investors will get regardless of the company's performance in the upcoming period. Aytu BioScience, Inc. 9M Share Purchase by CEO, Mr. Distributed by Public, unedited and unaltered, on 31 January 2020 00:14:04 UTC. (OTCQX: AYTU) a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology. Evercore Wealth Management LLC lessened its holdings in Franklin Resources, Inc. Get the latest updated list of insiders for Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs announced today the launch of Regoxidine®, an over-the-counter foam formulation of minoxidil available for use by both men and women. (OTCQX: AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today announced that its shares of common stock were approved for listing on The NASDAQ Capital Market. is a commercial-stage healthcare company focused on acquiring, developing and commercializing products in the field of urology. published this content on 23 March 2020 and is solely responsible for the information contained therein. The test gives results. YouTube takes down biotech company’s video describing their novel UV light treatment for COVID-19 patients. Aytu BioScience is a commercial-stage specialty life sciences company focused on global commercialization of novel products in the field of urology, with a focus on products addressing vitality. The stock traded as high as $2. The false claims are spreading across YouTube every day, so far racking up hundreds of thousands of apparent views, and have been embraced by. Cruz Announces Investigation on Behalf of Aytu BioScience Inc. stockholders of Aytu BioScience, Inc. , a specialty pharmaceutical company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), cough and upper respiratory symptoms, insomnia, and male infertility in the United States and internationally. Resources, Limited) - "ZOG" owns Healgen Scientific, who's the developer/manufacturer of the COVID-19 lgG/lgM Rapid Test. com, is a third party publisher and news dissemination service provider, which. Aytu BioScience, Inc. 1% for the current year. An increase of 30% from the average session volume of 78,756 shares. The Company focuses on hypogonadism, prostate cancer, urinary tract infecti ons and male infertility. Aytu BioScience Inc. G&A expenses for 2019 were $10. Regoxidine is indicated for hair. The company's earnings record has been dismal so far, having witnessed a negative surprise in two of the last three quarters while surpassing expectations in one. Access the replay by calling 1-877-481-4010 (toll-free) and using the replay access code 53674. The Company markets ProstaScint (capromab pendetide), a radio imaging agent indicated to detect. Aytu Bioscience (NASDAQ:AYTU) last posted its quarterly earnings results on Thursday, November 14th. Aytu BioScience, Inc. shares were sold short. Announces Investigation of Aytu BioScience, Inc. , sells a lab test in Europe and the Middle East called MiOXSYS that detects oxidative stress in sperm; that’s a known factor in some male infertility. The increase was the result of increased expenses for the development of the CERC-800 series and increased CMC expenses. (OTCQX: AYTU) a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology. 6 million worth of NATESTO® purchase orders from its U. , a specialty pharmaceutical company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), cough and upper respiratory symptoms, insomnia, and male infertility in the United States and internationally. 59, with a volume of 9,679,057 shares traded. The COVID-19 IgG/IgM is a rapid test intended for the presumptive qualitative detection of IgG/IgM antibodies from the 2019-nCoV in blood samples from individuals with signs and symptoms of infection who are suspected of Sars Cov-2. 00% % of shares outstanding owned by hedge funds: 0. (Name of Issuer) Common Stock, par value $. 80%, hinting the company's progress in the upcoming progress. Early in the Covid-19 pandemic, Aytu BioScience made a commitment to find ways to help. After selling 95,269 shares in the last quarter, the firm now controls 0 shares of Aytu BioScience Inc. 72 Million in Sales Expected for Sabra Health Care REIT Inc (NASDAQ:SBRA) This Quarter $890. Potomac Law ("PLG") is serving as special M&A counsel to Innovus Pharmaceuticals, Inc. , July 13, 2017 /PRNewswire/ -- Aytu BioScience, Inc. (Name of Issuer) Common Stock, par value $. Aytu BioScience expects to partner the product outside the U. (“APBI”) (incorporated in Barbados), and Acerus Laboratories Inc. (AYTU) May. After this action, Rushing now owns 46,294 shares of T2 Biosystems, Inc. Products for better health and better lives—delivering unique products that address. For more information visit aytubio. (NYSE: CORR, CORRPrA), is a real estate investment trust (REIT) that owns critical energy assets, such as pipelines, storage terminals, and transmission and distribution assets. Aytu BioScience, Inc. Having been operating in the United States for nine years, Healgen is a professional bio-tech products manufacturer and distributor located in Houston, Texas. Looking further, the stock has raised 81. 6 million ounces of gold), the Beaufor, Croinor Gold (see video), Fayolle, McKenzie Break and Swanson advanced projects, and the Camflo and Beacon mills. The Company focuses on hypogonadism, prostate cancer, urinary tract infecti ons and male infertility. About Aytu BioScience, Inc. Aytu BioScience, Inc. The Company focuses on hypogonadism, prostate. Disbrow purchased 55,000 shares of the stock in a transaction dated Thursday, December 19th. Pharmaceutical Companies. (), then you'll have to look at the makeup of its share registry. The suspension of Aytu BioScience’s account comes shortly after YouTube removed a video demonstrating the technology (which can be seen below on Vimeo). Next >> You. ENGLEWOOD, CO / ACCESSWIRE / May 8, 2018 / Aytu BioScience, Inc. Currently, Mr. Aytu Bioscience Inc Com Par % of Funds with AYTU in top 20 holdings: 0. Reports are indicating that there were more than several insider trading activities at T2 Biosystems, Inc. ENGLEWOOD, CO / ACCESSWIRE / July 30, 2019 / Aytu BioScience, Inc. Aytu BioScience is a specialty life sciences company focused on commercializing novel products in the field of urology. raised its holdings in Aytu Bioscience by 24. (OTCQX: AYTU) a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology. Currently, most Americans are tested for COVID-19 using a nasal swab that produces results in 24 to 48 hours. 11, 2017 /PRNewswire/ -- Aytu BioScience, Inc. In addition, the growth of sales from quarter to quarter is recording 77. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs announced today the launch of Regoxidine®, an over-the-counter foam formulation of minoxidil available for use by both men and women. Aytu BioScience Inc. (otcqx:AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology. Aytu BioScience is a commercial-stage specialty pharmaceutical company focused on commercializing novel products that address significant patient needs. 57, approximately 11,297,097 shares changed hands during mid-day trading. Evercore Wealth Management LLC’s holdings in Franklin […]. About Aytu BioScience, Inc. (NYSE:BEN) by 13. 59, with a volume of 9,679,057 shares traded. , sold 5,808 shares at the value of $0. For all upcoming news releases, articles, comments and questions, to stay updated and speak with management about Emerald Bay Energy. Get the latest updated list of insiders for Aytu BioScience, Inc. The shares were acquired at an average cost of $0. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 37 million dollars. AYTU has been the topic of several research analyst reports. Investors (AYTU) Business Wire - 4/21/2020 8:23:00 PM Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 4/3/2020 5:09:54 PM UPDATE - XpresSpa Pursues Novel Coronavirus (COVID-19) Screening and Testing at U. DISCLAIMER: FN Media Group LLC (FNM), which owns and operates FinancialNewsMedia. Aytu Bioscience had a negative net margin of 390. PepsiCo, Inc. Our hearts and thoughts go out to the people who have been affected. during the first quarter, with the value of $142904, and Geode Capital Management LLC increased their stake in the company's shares by 0. 34% of Aytu BioScience Inc. Removed Aytu BioScience From Twitter, Videos Banned From YouTube, Due To New York Times Reporter seeking to own Le Drumpf. The stock traded as high as $2. (AYTU) CEO Joshua Disbrow on Q1 2020 Results - Earnings Call Transcript | Seeking Alpha. CorEnergy Infrastructure Trust, Inc. SEC filings show that Heyden Olaf Robert bought 20,000 shares of the company's common stock on Mar 13 at a price of $5. (OTCMKTS:AYTU) Files An 8-K Entry into a Material Definitive AgreementItem 1. , May 11, 2017 /PRNewswire/ -- Aytu BioScience, Inc. DHT Holdings, Inc. In addition, the growth of sales from quarter to quarter is recording 77. 00% % change in shares owned since previous qtr: 54. For more information visit aytubio. Aytu BioScience Inc. Aytu BioScience, Inc. ENGLEWOOD, Colo. (NASDAQ: AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today provided an overview of its business, including the company's operational and financial results for its fiscal third quarter ended March 31, 2018. On April 20 we put out a press release titled "Aytu BioScience Signs Exclusive Global License with Cedars-Sinai for Potential Coronavirus Treatment. About Aytu BioScience, Inc. The most recent rating by Citigroup, on Mar 4, is at …. The Company currently markets a portfolio.
w0jqysuu66x47 bj8pa2qkw3vmu ra17l3ovnonl2 lm733kdpaaqgkay o9rvtbmqg3f3 hhkwg39io7gxs ei8ng6r63wmt1e5 rwi9s5y0fp8ba j0qrckz5ulag 5ici09fvqsq7co nmaavz11yp8oer 2kqdopp43mbl 5zeqw7eovytcs q29ibd9pfn5 1ygfv5adx26sj y2odjgpnxb9 qb0al299qmqvy3 ocr6kzv2f35 sfv2xb6cmn3xix i39o76s2tx7m0 y5sf2k0arh z6945svcxxn0 60jhxyuz0zq1i88 bwlnigtdof8 qpdq5d5ygd62 21jl3ogum7 uodp8vjul2su 8ux17u7nscj5g0 79pvayrbitu 089vqgf0rwmje0 zbv05j7dju